Functional impacts of the diversity of the meningococcal factor H binding protein

Vaccine

Volumn 31, Issue 1, 2012, Pages 183-189

  Hong, Eva ^a   Giorgini, Dario ^a   Deghmane, Ala Eddine ^a   Taha, Muhamed Kheir ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Bactericidal; Complement binding; Diversity; Neisseria meningitidis; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BINDING PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; FACTOR H BINDING PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; COMPLEMENT DEPOSITION; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 84870495111     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.072     Document Type: Article

References (27)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., Hughes J.M. Meningococcal disease. N Engl J Med 2001, 344(18):1378-1388.
2. Maiden M.C. Population genetics of a transformable bacterium: the influence of horizontal genetic exchange on the biology of Neisseria meningitidis. FEMS Microbiol Lett 1993, 112(3):243-250.
3. Taha M.K., Deghmane A.E., Antignac A., Zarantonelli M.L., Larribe M., Alonso J.M. The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol 2002, 10(8):376-382.
4. Granoff D.M., Welsch J.A., Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 2009, 77(2):764-769.
5. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458(7240):890-893.
6. Findlow J., Borrow R., Snape M.D., Dawson T., Holland A., John T.M., et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010, 51(10):1127-1137.
7. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
8. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95(6):3140-3145.
9. Taha M.K., Giorgini D., Ducos-Galand M., Alonso J.M. Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol 2004, 42(9):4158-4163.
10. Thompson E.A., Feavers I.M., Maiden M.C. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003, 149(Pt 7):1849-1858.
11. Deghmane A.E., Petit S., Topilko A., Pereira Y., Giorgini D., Larribe M., et al. Intimate adhesion of Neisseria meningitidis to human epithelial cells is under the control of the crgA gene, a novel LysR-type transcriptional regulator. EMBO J 2000, 19(5):1068-1078.
12. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27(21):2794-2803.
13. Jolley K.A., Maiden M.C. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinform 2010, 11:595.
14. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000, 287(5459):1809-1815.
15. Zarantonelli M.L., Antignac A., Lancellotti M., Guiyoule A., Alonso J.M., Taha M.K. Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice. J Antimicrob Chemother 2006, 57(5):924-930.
16. Taha M.K., Morand P.C., Pereira Y., Eugene E., Giorgini D., Larribe M., et al. Pilus-mediated adhesion of Neisseria meningitidis: the essential role of cell contact-dependent transcriptional upregulation of the PilC1 protein. Mol Microbiol 1998, 28(6):1153-1163.
17. Cheadle C., Vawter M.P., Freed W.J., Becker K.G. Analysis of microarray data using Z score transformation. J Mol Diagn 2003, 5(2):73-81.
18. Caron F., du Chatelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11(6):455-463.
19. Zipfel P.F., Skerka C., Hellwage J., Jokiranta S.T., Meri S., Brade V., et al. Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 2002, 30(Pt 6):971-978.
20. Deghmane A.E., Parent du Chatelet I., Szatanik M., Hong E., Ruckly C., Giorgini D., et al. Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis 2010, 202(2):247-250.
21. Zarantonelli M.L., Lancellotti M., Deghmane A.E., Giorgini D., Hong E., Ruckly C., et al. Hyperinvasive genotypes of Neisseria meningitidis in France. Clin Microbiol Infect 2008, 14(5):467-472.
22. Tsang R.S., Tsai C.M., Zhu P., Ringuette L., Lorange M., Law D.K. Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada. J Clin Microbiol 2004, 42(4):1460-1465.
23. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, 107(45):19490-19495.
24. Seib K.L., Brunelli B., Brogioni B., Palumbo E., Bambini S., Muzzi A., et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 2011, 79(2):970-981.
25. Lucidarme J., Tan L., Exley R.M., Findlow J., Borrow R., Tang C.M. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011, 18(6):1002-1014.
26. European Centre for Disease Prevention and Control Surveillance of invasive bacterial diseases in Europe 2008/2009 2011, ECDC, Stockholm.
27. Lewis L.A., Ngampasutadol J., Wallace R., Reid J.E., Vogel U., Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 2010, 6(7):e1001027.